Mesenchymal stem cells (MSC) offer a novel approach to treatment of inflammatory disorders in humans and companion animals. Cats spontaneously develop a wide variety of inflammatory disorders and may potentially benefit from MSC-based therapies. Multiple genes are involved in immunomodulation by MSC and interspecies differences between expressions of these genes exist. The goals of the study were to characterize the expression of genes known to be involved in MSC-based immunomodulation and determine the effect of MSC on proliferation of T cells in coculture experiments with peripheral blood mononuclear cells (PBMC). Unstimulated MSC expressed all immunomodulatory genes studied except for IL-10. Levels of iNOS and FASL were low or undetectable at the RNA level. INFγ stimulation resulted in significant dose-dependent upregulation of IDO1, PD-L1, IL-6, COX2, and HGF. Levels of kynurenine were increased after 3-day incubation with INFγ. TNFα stimulation increased expression of IL-6 at both RNA and protein level as well as upregulated COX2 gene expression and PTGES1.Stimulation with both INFγ and TNFα resulted in significant increase in PGE2 levels in cell culture medium. MSC significantly decreased proliferation of ConA-stimulated PBMC in coculture experiments at 1:5 ratio. Our results suggest that feline MSC have similar immunomodulatory gene expression and react to inflammatory cytokines in a manner similar to human MSC. Thus, MSC may play an important role in treatment of feline disease as well as serve as an important translational species to evaluate MSC-based therapies of diseases common to both humans and cats.
Get full access to this article
View all access options for this article.
References
1.
FriedensteinA, DeriglasovaU, KulaginaN, PanasukA, RudakowaS, LuriáE and RuadkowI. (1974). Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol, 2:83–92.
2.
AggarwalS and PittengerMF. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 105:1815–1822.
3.
DjouadF, CharbonnierLM, BouffiC, Louis-PlenceP, BonyC, ApparaillyF, CantosC, JorgensenC and NoelD. (2007). Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells, 25:2025–2032.
4.
BrownJM, NemethK, Kushnir-SukhovNM, MetcalfeDD and MezeyE. (2011). Bone marrow stromal cells inhibit mast cell function via a COX2-dependent mechanism. Clin Exp Allergy, 41:526–534.
5.
NemethK, LeelahavanichkulA, YuenPS, MayerB, ParmeleeA, DoiK, RobeyPG, LeelahavanichkulK, KollerBH, et al. (2009). Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med, 15:42–49.
6.
Di NicolaM. (2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood, 99:3838–3843.
7.
JiangXX, ZhangY, LiuB, ZhangSX, WuY, YuXD and MaoN. (2005). Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood, 105:4120–4126.
8.
SpaggiariGM, CapobiancoA, AbdelrazikH, BecchettiF, MingariMC and MorettaL. (2008). Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood, 111:1327–1333.
9.
BrandauS, JakobM, HemedaH, BruderekK, JaneschikS, BootzF and LangS. (2010). Tissue-resident mesenchymal stem cells attract peripheral blood neutrophils and enhance their inflammatory activity in response to microbial challenge. J Leukoc Biol, 88:1005–1015.
10.
EngelaAU, HoogduijnMJ, BoerK, LitjensNH, BetjesMG, WeimarW and BaanCC. (2013). Human adipose-tissue derived mesenchymal stem cells induce functional de-novo regulatory T cells with methylated FOXP3 gene DNA. Clin Exp Immunol, 173:343–354.
11.
PengY, ChenX, LiuQ, ZhangX, HuangK, LiuL, LiH, ZhouM, HuangF, et al. (2015). Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5+ regulatory B cells producing interleukin 10. Leukemia, 29:636–646.
12.
Castelo-BrancoMT, SoaresID, LopesDV, BuongustoF, MartinussoCA, do RosarioAJr., SouzaSA, GutfilenB, FonsecaLM, et al. (2012). Intraperitoneal but not intravenous cryopreserved mesenchymal stromal cells home to the inflamed colon and ameliorate experimental colitis. PLoS One, 7:e33360.
13.
NemethK, Keane-MyersA, BrownJM, MetcalfeDD, GorhamJD, BundocVG, HodgesMG, JelinekI, MadalaS, KarpatiS and MezeyE. (2010). Bone marrow stromal cells use TGF-β to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc Natl Acad Sci USA, 107:5652–5657.
14.
TrzilJE, MasseauI, WebbTL, ChangCH, DodamJR, CohnLA, LiuH, QuimbyJM, DowSW and ReineroCR. (2014). Long-term evaluation of mesenchymal stem cell therapy in a feline model of chronic allergic asthma. Clin Exp Allergy, 44:1546–1557.
KrugerJM, OsborneCA and LulichJP. (2009). Changing paradigms of feline idiopathic cystitis. Vet Clin North Am Small Anim Pract, 39:15–40.
17.
De CockHEV, FormanMA, FarverTB and MarksSL. (2007). Prevalence and Histopathologic Characteristics of Pancreatitis in Cats. Vet Pathol, 44:39–49.
18.
MarinoCL, LascellesBDX, VadenSL, GruenME and MarksSL. (2014). Prevalence and classification of chronic kidney disease in cats randomly selected from four age groups and in cats recruited for degenerative joint disease studies. J Feline Med Surg, 16:465–472.
19.
TrepanierL. (2009). Idiopathic inflammatory bowel disease in cats: rational treatment selection. J Feline Med Surg, 11:32–38.
20.
ChinnaduraiR, CoplandIB, PatelSR and GalipeauJ. (2014). IDO-independent suppression of T cell effector function by IFN-gamma-licensed human mesenchymal stromal cells. J Immunol, 192:1491–1501.
GuY-z, XueQ, ChenY-j, YuG-H, QingM-d, ShenY, WangM-y, ShiQ and ZhangX-G. (2013). Different roles of PD-L1 and FasL in immunomodulation mediated by human placenta-derived mesenchymal stem cells. Hum Immunol, 74:267–276.
23.
ChabannesD, HillM, MerieauE, RossignolJ, BrionR, SoulillouJP, AnegonI and CuturiMC. (2007). A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood, 110:3691–3694.
24.
RenG, SuJ, ZhangL, ZhaoX, LingW, L'HuillieA, ZhangJ, LuY, RobertsAI, et al. (2009). Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells, 27:1954–1962.
25.
RenG, ZhangL, ZhaoX, XuG, ZhangY, RobertsAI, ZhaoRC and ShiY. (2008). Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell, 2:141–150.
26.
NeupaneM, ChangC-C, KiupelM and Yuzbasiyan-GurkanV. (2008). Isolation and characterization of canine adipose–derived mesenchymal stem cells. Tissue Eng Part A, 14:1007–1015.
27.
ParysM, NelsonN, KoehlK, MillerR, KaneeneJB, KrugerJM and Yuzbasiyan-GurkanV. (2015). Safety of intraperitoneal injection of adipose tissue-derived autologous mesenchymal stem cells in cats. J Vet Intern Med, 30:157–163.
28.
WebbTL, QuimbyJM and DowSW. (2012). In vitro comparison of feline bone marrow-derived and adipose tissue-derived mesenchymal stem cells. J Feline Med Surg, 14:165–168.
29.
QuimbyJM, WebbTL, GibbonsDS and DowSW. (2011). Evaluation of intrarenal mesenchymal stem cell injection for treatment of chronic kidney disease in cats: a pilot study. J Feline Med Surg, 13:418–426.
30.
ReineroCR, LiuH and ChangC-H. (2012). Flow cytometric determination of allergen-specific T lymphocyte proliferation from whole blood in experimentally asthmatic cats. Vet Immunol Immunopathol, 149:1–5.
31.
PfafflMW. (2001). A new mathematical model for relative quantification in real-time RT–PCR. Nucleic Acids Res, 29:e45.
BraunD, LongmanRS and AlbertML. (2005). A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood, 106:2375–2381.
34.
MeiselR, ZibertA, LaryeaM, GobelU, DaubenerW and DillooD. (2004). Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood, 103:4619–4621.
35.
SatoK, OzakiK, OhI, MeguroA, HatanakaK, NagaiT, MuroiK and OzawaK. (2007). Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood, 109:228–234.
36.
WatermanRS, TomchuckSL, HenkleSL and BetancourtAM. (2010). A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One, 5:e10088.
37.
LiP, LiSH, WuJ, ZangWF, DhingraS, SunL, WeiselRD and LiRK. (2013). Interleukin-6 downregulation with mesenchymal stem cell differentiation results in loss of immunoprivilege. J Cell Mol Med, 17:1136–1145.
38.
ChangC-J, YenM-L, ChenY-C, ChienC-C, HuangH-I, BaiC-H and YenBL. (2006). Placenta-Derived Multipotent Cells Exhibit Immunosuppressive Properties That Are Enhanced in the Presence of Interferon-γ. Stem Cells, 24:2466–2477.
39.
Luz-CrawfordP, NoelD, FernandezX, KhouryM, FigueroaF, CarrionF, JorgensenC and DjouadF. (2012). Mesenchymal stem cells repress Th17 molecular program through the PD-1 pathway. PLoS One, 7:e45272.
40.
MougiakakosD, JitschinR, JohanssonCC, OkitaR, KiesslingR and Le BlancK. (2011). The impact of inflammatory licensing on heme oxygenase-1–mediated induction of regulatory T cells by human mesenchymal stem cells. Blood, 117:4826–4835.
41.
RasmussonI, RingdénO, SundbergB and Le BlancK. (2005). Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res, 305:33–41.
42.
RyanJM, BarryF, MurphyJM and MahonBP. (2007). Interferon-γ does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol, 149:353–363.
43.
NaldiniL, VignaE, BardelliA, FollenziA, GalimiF and ComoglioPM. (1995). Biological Activation of pro-HGF (Hepatocyte Growth Factor) by Urokinase Is Controlled by a Stoichiometric Reaction. J Biol Chem, 270:603–611.
44.
EnglishK, BarryFP, Field-CorbettCP and MahonBP. (2007). IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol Lett, 110:91–100.
45.
DelaRosaO, LombardoE, BerazaA, Mancheño-CorvoP, RamirezC, MentaR, RicoL, CamarilloE, GarcíaL, et al. (2009). Requirement of IFN-γ–mediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose–derived stem cells. Tissue Eng Part A, 15:2795–2806.
46.
ArziB, Mills-KoE, VerstraeteFJM, KolA, WalkerNJ, BadgleyMR, FazelN, MurphyWJ, VapniarskyN and BorjessonDL. (2016). Therapeutic Efficacy of Fresh, Autologous Mesenchymal Stem Cells for Severe Refractory Gingivostomatitis in Cats. Stem Cells Transl Med, 5:75–86.
47.
KolA, ArziB, AthanasiouKA, FarmerDL, NoltaJA, RebhunRB, ChenX, GriffithsLG, VerstraeteFJM, MurphyCJ and BorjessonDL. (2015). Companion animals: translational scientist's new best friends. Sci Transl Med, 7:308ps21.
48.
SeokJ, WarrenHS, CuencaAG, MindrinosMN, BakerHV, XuW, RichardsDR, McDonald-SmithGP, GaoH, et al.; Inflammation and LSCRP Host Response to Injury. (2013). Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA, 110:3507–3512.
49.
MestasJ and HughesCCW. (2004). Of Mice and Not Men: differences between Mouse and Human Immunology. J Immunol, 172:2731–2738.
50.
BolkerJ. (2012). Model organisms: there's more to life than rats and flies. Nature, 491:31–33.
51.
OsuchowskiMF, RemickDG, LedererJA, LangCH, AasenAO, AibikiM, AzevedoLC, BahramiS, BorosM, et al. (2014). Abandon the mouse research ship? Not just yet!. Shock, 41:463–475.
52.
MellanbyRJ. (2015). Our time is now–how companion animal veterinarians can transform biomedical science. J Small Anim Pract, 56:689–692.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
